Blog
RSS FeedPosted by Michael Wonder on 03 Apr 2026
NHS patients and British businesses to benefit from historic changes to medicines access following pharmaceutical partnership with US
2 April 2026 - New partnership accelerates NHS patients' access to new medicines and will see UK benefit from greater life ...
Posted by Michael Wonder on 17 Oct 2025
Same time decisions on licensing and value - what pharmaceutical companies need to know
10 October 2025 - Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and ...
Posted by Michael Wonder on 13 Feb 2025
NICE joins international collaboration on HTA methods research
12 February 2025 - We’ve partnered with the US based ICER and the Canadian Drug Agency (CDA-AMC) to establish the Health ...
Posted by Michael Wonder on 23 Jan 2025
EU-HTA: maintaining the achievements of AMNOG
20 January 2025 - IQWiG welcomes the fact that the adjustments to the AMNOG procedure planned for the integration with European ...
Posted by Michael Wonder on 17 Jan 2025
International collaboration provides new guidance on the use of surrogate outcomes in cost effectiveness analysis
17 January 2025 - Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits ...
Posted by Michael Wonder on 16 Dec 2024
Findings from the EUnetHTA 21 project for EU-HTA from 2025
12 December 2024 - The results from EUnetHTA 21 provide insights for future cooperation in EU-HTA: participants from IQWiG and ...
Posted by Michael Wonder on 16 May 2024
Delegation from Taiwan visits IQWiG
15 May 2024 - At the end of April 2024, Mao-Ting Sheen visited the Institute for Quality and Efficiency in Healthcare ...
Posted by Michael Wonder on 18 Mar 2024
Co-design of an enhanced consumer engagement process
18 March 2024 - A consumer-led Co-design Working Group has developed proposed recommendations for enhancing consumer engagement processes to enable ...
Posted by Michael Wonder on 04 Mar 2024
Together for high standards in the assessment of health technologies in Europe from 2025
1 March 2024 - A few months before the EU HTA regulation came into force, a delegation from the French HTA ...
Posted by Michael Wonder on 06 Feb 2024
Updates on NICE and SMC collaboration on MTA for cystic fibrosis
1 February 2024 - On 19 December 2023, we advised that NICE would be liaising with key stakeholders to determine ...
Posted by Michael Wonder on 25 Jan 2024
PHARMAC joins global health technology assessment network
25 January 2024 - PHARMAC has joined the International Network of Agencies for Health Technology Assessment (INAHTA) - a network ...
Posted by Michael Wonder on 20 Oct 2023
Ethical and legal considerations in social media research for health technology assessment: conclusions from a scoping review
20 October 2023 - The objective was to identify and describe the published guidance and current academic discourse of ethical issues ...
Posted by Michael Wonder on 20 Sep 2023
International HTA collaboration expands
20 September 2023 - The international collaboration between six health technology assessment bodies from across the UK, Australia and Canada ...
Posted by Michael Wonder on 24 Aug 2023
International heath technology assessment collaboration expands
24 August 2023 - The international collaboration between six health technology assessment bodies from across the UK, Australia and Canada has ...
Posted by Michael Wonder on 10 Aug 2023
Patient and citizen participation at the organisational level in health technology assessment: an exploratory study in five jurisdictions
8 August 2023 - While patient participation in individual health technology assessments has been frequently described in the literature, patient and ...